You are here

Pfizer's case highlights the lengths US firms will go to lower taxes

ofizer.jpg
Long before Pfizer conceived of merging with Allergan in a US$150 billion deal to rid itself of what its chief executive called an "an uncompetitive tax rate" in the United States, the company was deploying various tax avoidance strategies dating back to at least 1976.

New York

LONG before Pfizer conceived of merging with Allergan in a US$150 billion deal to rid itself of what its chief executive called an "an uncompetitive tax rate" in the United States, the company was deploying various tax avoidance strategies dating back to at least 1976.